Explore personalized therapies with our pharmacy team. Talk to a pharmacist today! →
Peptides and the Evolving Compounding Landscape
Emerging science. Growing clinical interest. An evolving regulatory pathway. The regulatory landscape has changed. Here is what you need to know before you prescribe.
Peptides are not new to medicine. These short chains of amino acids occur naturally throughout the body, and peptide-based therapies have been studied and used in various forms for decades. Today, however, a distinct group of peptides is generating increased attention across functional, integrative and specialty medicine for its potential roles in tissue repair, inflammatory signaling, metabolism, neurological function, sleep and healthy aging.
Peptide therapy is not a single category of treatment. Individual peptides have distinct mechanisms, proposed applications and levels of supporting evidence. While some peptide-based drugs are well established in medicine, many of the specific peptides attracting attention today remain investigational, with evidence ranging from preclinical research to limited human studies.
Recent FDA activity has brought additional attention to several of these substances and their potential future role in traditional pharmacy compounding.
Pharmacy Solutions does not currently offer the peptides discussed on this page. We are closely monitoring the science, FDA actions and evolving regulatory landscape so we can help keep our provider partners informed.
What Are Peptides?
Peptides are short chains of amino acids that can act as signaling molecules throughout the body. Their biological activity depends on their amino acid sequence, structure and the pathways with which they interact.
This diversity is one reason peptides are being investigated across such a broad range of clinical areas. Depending on the individual peptide, research is exploring potential roles in inflammatory pathways, tissue repair, cellular metabolism, neurological signaling, circadian regulation and other physiological processes.
It is also why peptides need to be evaluated individually. Research supporting one peptide cannot be assumed to establish the safety or effectiveness of another.
Why Are Peptides Generating So Much Interest?
Peptides can interact with highly specific biological pathways, creating opportunities for researchers to investigate targeted approaches to a variety of physiological processes.
For providers, the emerging research spans areas as diverse as gastrointestinal and inflammatory conditions, tissue repair and recovery, metabolic function, cognition, sleep and healthy aging.
The level of evidence, however, varies considerably. Some of the peptides attracting attention are supported primarily by laboratory and animal research, while others have limited human data or a history of clinical investigation outside the United States.
Promising mechanisms and preclinical findings do not necessarily translate into established clinical safety and effectiveness. Appropriate dosing, long-term safety, contraindications and drug interactions also remain incompletely characterized for several of these substances.
More Resources for Your Health Journey
Compounding is always changing, especially when it comes to areas like peptides. Pharmacy Solutions stays on top of the latest regulations and keeps us informed about what’s available and appropriate. It’s reassuring to have a pharmacy partner we can turn to when we have questions and are considering options for our patients.
Jordan M., MD
Peptides Providers Are Watching
In July 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) evaluated seven peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon.
Here is a closer look at each and why it has generated research interest.
BPC-157
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. Research has focused largely on its potential relationship to tissue repair and gastrointestinal processes.
Preclinical studies have explored BPC-157 in areas including tendon and ligament healing, angiogenesis, collagen formation, gastrointestinal inflammation and wound healing. Proposed mechanisms involve several biological pathways associated with tissue repair, including nitric oxide and VEGF signaling.
Much of this evidence comes from animal and preclinical research. Long-term human safety, appropriate dosing and contraindications remain inadequately characterized.
KPV
KPV is a three-amino-acid peptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone involved in inflammatory and immune responses.
Research has focused particularly on inflammatory signaling, including the NF-κB pathway and pro-inflammatory cytokines. Gastrointestinal inflammation has been an area of particular interest, along with research involving skin, wound healing and immune-related pathways.
Researchers have also investigated different delivery routes for KPV, including oral, topical and injectable administration.
TB-500
TB-500 is a synthetic peptide related to Thymosin Beta-4, a naturally occurring protein involved in cell migration and tissue repair.
Research interest has centered on processes involved in recovery and regeneration, including cell migration, angiogenesis, inflammation and tissue remodeling. This has led to investigation of potential applications involving musculoskeletal injuries, wound healing and tissue repair.
Long-term human data remain limited, making the distinction between research interest and established clinical benefit especially important.
MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded by mitochondrial DNA. It is involved in cellular metabolism and energy regulation, making it distinct from many of the other peptides currently attracting clinical interest.
Research is exploring its relationship to AMPK signaling, glucose utilization, insulin sensitivity, mitochondrial function and metabolic stress. Potential areas of investigation include metabolic health, body composition, energy and age-related metabolic changes.
Human clinical data and long-term safety information are still developing.
Semax
Semax is a synthetic seven-amino-acid peptide derived from a fragment of adrenocorticotropic hormone (ACTH 4–10). It was originally developed in Russia and has been studied primarily for neurological and cognitive applications.
Research has examined its potential effects on neurotrophic signaling, neurotransmitter pathways, neuroprotection and stress response. Areas of investigation have included attention and cognition, cerebral ischemia, neurological recovery and neuroinflammation.
Available evidence includes preclinical research, regional clinical experience and smaller clinical investigations rather than large, modern multicenter trials.
Epitalon
Epitalon, also called Epithalon, is a synthetic four-amino-acid peptide derived from epithalamin, a peptide complex originally isolated from the pineal gland.
Research has focused on cellular aging, circadian regulation and neuroendocrine signaling. Investigators have explored potential effects involving melatonin regulation, oxidative stress, gene expression and telomerase activity.
Much of the available evidence comes from preclinical research, historical longevity research and smaller regional human studies rather than modern large-scale controlled clinical trials.
Emideltide (DSIP)
Emideltide is associated with Delta Sleep-Inducing Peptide (DSIP), a nine-amino-acid neuropeptide historically studied for its potential role in sleep regulation, neuroendocrine modulation and stress response.
Research has explored potential effects on sleep architecture, the hypothalamic-pituitary-adrenal axis, neurotransmitter signaling and autonomic nervous system function. FDA’s recent consideration of Emideltide included proposed applications involving opioid withdrawal, chronic insomnia and narcolepsy.
Available human data remain limited, and long-term safety, optimal dosing, contraindications and drug interactions are not well established.
What Happened at the FDA?
On July 23 and 24, 2026, PCAC considered these seven peptide-related bulk drug substances for possible inclusion on the FDA’s Section 503A Bulks List.
The committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for inclusion. Emideltide did not receive a favorable recommendation.
That distinction is important: an advisory committee recommendation is not FDA approval.
PCAC provides independent recommendations to help inform FDA decision-making. Its votes are not legally binding, and FDA is not required to follow them. The favorable recommendations also did not immediately add the six substances to the 503A Bulks List or authorize pharmacies to begin compounding them.
Additional FDA action is required before any changes become official.
Where Could Compounding Fit Into the Picture?
Section 503A provides the federal framework for traditional patient-specific pharmacy compounding. Among other requirements, a licensed pharmacist may prepare a compounded medication for an individually identified patient pursuant to a valid prescription when an appropriate clinical need exists and applicable federal and state requirements are satisfied.
When a pharmacy compounds from a bulk drug substance, federal law also places restrictions on which substances may be used. One pathway is inclusion on FDA’s 503A Bulks List.
That is why the recent PCAC proceedings matter to the compounding community. If FDA ultimately takes action to add any of these substances to the Bulks List, it could change the regulatory pathway through which qualifying 503A pharmacies and prescribers may consider patient-specific compounded preparations.
Importantly, eligibility for compounding would not make a peptide FDA-approved or establish its safety or effectiveness for a particular indication. Compounded medications do not undergo the same FDA premarket review for safety, effectiveness and quality as FDA-approved manufactured drugs.
Why Pharmacy Oversight Matters
Growing interest in peptides has also contributed to an online marketplace for products sold as “research chemicals” or labeled “for research use only.”
For providers and patients, the source matters.
Products obtained outside regulated pharmacy channels may present questions about identity, concentration, purity, sterility, storage conditions and manufacturing origin. A prescription-based pharmacy pathway, when legally available, introduces professional oversight, sourcing and documentation requirements, and pharmacist-prescriber collaboration.
As the peptide landscape develops, these distinctions will remain important to informed clinical decision-making.
What Providers Should Know as the Landscape Evolves
The July 2026 PCAC recommendations represent an important step, but not the final one.
For now, providers interested in peptides should continue to evaluate each substance individually based on the quality of available evidence, the patient’s health history, applicable federal and state requirements and established standards of care.
It is equally important to distinguish among:
- FDA-approved peptide-based medications, which have undergone FDA review
- Patient-specific compounded preparations, when legally permissible, which follow a separate regulatory framework and are not FDA-approved
- Products sold outside regulated pharmacy channels, including products marketed online for “research use only.”
Pharmacy Solutions is monitoring FDA actions, regulatory developments and emerging clinical research so we can help our provider partners understand what changes—and what doesn’t—as this field evolves.
Frequently Asked Questions About Peptides
Does Pharmacy Solutions currently compound these peptides?
No. Pharmacy Solutions does not currently offer BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon or Emideltide.
We are closely following FDA action, the evolving regulatory landscape and available clinical evidence and will keep our provider partners informed as meaningful developments occur.
Did FDA approve these peptides in July 2026?
No. The July votes came from FDA’s Pharmacy Compounding Advisory Committee and were recommendations, not FDA approvals.
The committee recommended six substances for inclusion on the 503A Bulks List, but FDA must take additional action before any changes become official.
Does inclusion on the 503A Bulks List mean a peptide is proven safe and effective?
No. Inclusion on the 503A Bulks List addresses whether a bulk drug substance may qualify for use in traditional pharmacy compounding under applicable conditions. It does not constitute FDA approval of the substance or establish safety or effectiveness for a particular clinical use.
Why are providers interested in these peptides?
The answer varies by peptide. Current research encompasses biological processes associated with tissue repair, inflammatory signaling, metabolism, neurological function, sleep and cellular aging.
The strength of evidence also varies substantially. For some peptides, much of the available research remains preclinical, while others have limited human or international clinical data.
Can providers contact Pharmacy Solutions with questions about peptides?
Yes. While Pharmacy Solutions does not currently offer the peptides discussed here, our team is following regulatory developments affecting compounding and can help providers understand updates as they occur.
Stay Informed as the Peptide Landscape Evolves
Peptides represent an intriguing and rapidly developing area of research. They also illustrate why emerging therapies require careful evaluation: a compelling biological mechanism or promising preclinical result is not the same as demonstrated clinical safety and effectiveness.
As FDA considers the next steps following the July 2026 advisory committee meeting, Pharmacy Solutions will continue monitoring the regulatory process and the science behind these emerging therapies.
Stay connected with Pharmacy Solutions for updates on peptides, compounding and what new developments may mean for your practice.
This content is intended for healthcare professionals for educational purposes only and does not constitute medical advice. Discussion of a peptide does not indicate that it is FDA-approved, legally available for compounding, appropriate for a particular patient or currently offered by Pharmacy Solutions.
Let’s Start a Conversation Have Questions or Want to Learn More? We’re Here to Help.
Whether you have a specific question, need additional information, or want to learn more about working with Pharmacy Solutions, our pharmacy team is here to help. Connect with a pharmacist to get answers and discuss your practice’s needs. Ready to get started? Register your practice to gain access to our full range of resources and stay connected with our team.
